NeuroBo Q1 net loss $6.7M; first patient dosed in DA-1726 obesity trial

MetaVia Inc.

2024-Q1 EPS reported -$1.32

Net loss of $6.7M ($1.32 per share) vs $2.6M ($0.51) in Q1 2023; R&D spend rose to $4.9M from $0.6M.
Cash $16.0M as of March 31, 2024, down from $22.4M at year-end 2023; expects runway into Q4 2024.
First patient dosed in Phase 1 SAD part of DA-1726 for obesity; top-line SAD data expected Q3 2024.
Phase 2a trial of DA-1241 for MASH fully enrolled in Part 1; Part 2 with sitagliptin enrolling; top-line data expected Q4 2024.
Appointed Marshall Woodworth as CFO (previously acting); exploring financing alternatives.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MetaVia Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and providing a corporate strategic update.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007475

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.